Restech is proud to announce the launch of PepsinCheck, a PEPTEST product branded for the U.S. consumer market
illi News/10065299

HOUSTON - illiNews -- UK healthcare innovator, RD Biomed, developed Peptest, the world's first non-invasive test for reflux, in 2007.  Since that time it has grown to global prominence. Shipping costs and wait times were a barrier to the U.S. market preventing the adoption of this direct to consumer diagnostic test. Now with Restech managing the PepsinCheck operations, the test is shipped from the U.S., processed at strategically located American labs, and results are sent back to the consumer by mail and a secure email within about a week.

Both PepsinCheck (U.S. market) and Peptest (non-U.S. markets) are manufactured by RD Biomed to the same global standard. The test detects the presence of the stomach enzyme pepsin (recognized as a reliable diagnostic biomarker for reflux) in saliva and sputum samples.

Restech VP of Clinical Affairs, Thomas Ball, commented, "As we Rethink Reflux across the continuum of care, direct to consumer healthcare plays a pivotal role.  RD Biomed and the Peptest provide an ideal accompaniment to our product portfolio, ensuring that tough diagnostic cases find appropriate physician-based care in addition to broadening our reach to an unprecedented range of patients. PepsinCheck represents the first at-home reflux testing in the US market and holds the potential to revolutionize the care of individuals with symptoms ranging from heartburn, to chronic cough, and even obstructive sleep apnea."

More on illi News

• Naperville Police Arrest Subject for Possession of Child Pornography
• Mayor Lori Lightfoot Announces Plan to Open Chicago's Streets to Support Businesses and Help Residents in Response to Covid-19
• Evolve IP Offers Rapid Deployment of Desktop as a Service to Ingram Micro Partners
• Chicago: Mayor Lightfoot Announces New Initiatives to Encourage Citywide Participation in the 2020 Census
• 626 acquires the assets of Innovatus CR and DR Business. The World Slows Down. We Move Faster

Professor Peter Dettmar, Director of RD Biomed, said: "We're thrilled that our salivary pepsin test for diagnosing reflux has officially launched in the US. It has been a pleasure working with Restech, a successful digestive health solutions company, and we could not have chosen a better company to distribute and commercialise PepsinCheck by Peptest."

About Restech

At Restech, we believe there is a better way to manage reflux. Our team designed and launched the first real-time sensor that could function highly accurately in a non-liquid environment. Since then, we've obsessed over reflux, developing and seeking out new products across the diagnostic and therapeutic continuum. www.restech.com

About RD Biomed & Peptest

RD Biomed is a pharmaceutical development and diagnostic company based at Castle Hill Hospital in Hull, East Yorkshire. Innovators in healthcare product development, RD Biomed focusses on gastroenterology and wound management and develops products that identify, prevent and treat various medical conditions.  www.peptest.co.uk

More on illi News

• Immunotherapy Drugs Market Worth $274.6 Billion by 2025 - Exclusive Report by MarketsandMarkets™
• R+M Development Closes on Refinance of Student Housing Project Amidst Pandemic
• Teenage mariachi ensemble records album during pandemic, keeping social distancing guidelines
• Getman Takes his Popular Book Fairs into the Virtual World Transforming the Way Buyers Meet Sellers of Rare Books, Maps, Prints and Ephemera
• Teleroute, Part of Alpega Group, launches an API Interface and a new Mobile App to help their growing number of customers work even more efficiently

CONTACTS

Thomas Ball
Vice President of Clinical Affairs
T: 1.800.352.1512
E: tball@restech.com

Harvey Dettmar
Director, RD Biomed Limited
T: +44 1482 461866
E: harvey.dettmar@technostics.com

www.pepsincheck.com